These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 20696321)

  • 21. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.
    Schwarzschild MA; Chen JF; Ascherio A
    Neurology; 2002 Apr; 58(8):1154-60. PubMed ID: 11971080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.
    Simola N; Morelli M; Pinna A
    Curr Pharm Des; 2008; 14(15):1475-89. PubMed ID: 18537671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The treatment of Parkinson's disease--adenosine A2A receptor antagonists].
    Matsubara E; Shoji M; Abe K
    Nihon Rinsho; 2002 Jan; 60(1):112-6. PubMed ID: 11808320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
    Cacciari B; Spalluto G; Federico S
    Mini Rev Med Chem; 2018; 18(14):1168-1174. PubMed ID: 29692248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenosine A2A receptors and depression.
    El Yacoubi M; Costentin J; Vaugeois JM
    Neurology; 2003 Dec; 61(11 Suppl 6):S82-7. PubMed ID: 14663017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
    Schwarzschild MA; Xu K; Oztas E; Petzer JP; Castagnoli K; Castagnoli N; Chen JF
    Neurology; 2003 Dec; 61(11 Suppl 6):S55-61. PubMed ID: 14663012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
    Petzer JP; Castagnoli N; Schwarzschild MA; Chen JF; Van der Schyf CJ
    Neurotherapeutics; 2009 Jan; 6(1):141-51. PubMed ID: 19110205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
    Chen JF; Xu K; Petzer JP; Staal R; Xu YH; Beilstein M; Sonsalla PK; Castagnoli K; Castagnoli N; Schwarzschild MA
    J Neurosci; 2001 May; 21(10):RC143. PubMed ID: 11319241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.
    Pinna A
    CNS Drugs; 2014 May; 28(5):455-74. PubMed ID: 24687255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
    Petzer JP; Petzer A
    Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.
    Ross GW; Petrovitch H
    Drugs Aging; 2001; 18(11):797-806. PubMed ID: 11772120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purinergic signaling in Parkinson's disease. Relevance for treatment.
    Navarro G; Borroto-Escuela DO; Fuxe K; Franco R
    Neuropharmacology; 2016 May; 104():161-8. PubMed ID: 26211977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenosine A
    Offit M; Nagle B; Ozay G; Zhang I; Kerasidis A; Torres-Yaghi Y; Pagan F
    Int Rev Neurobiol; 2023; 170():105-119. PubMed ID: 37741688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.
    Kulisevsky J; Poyurovsky M
    Eur Neurol; 2012; 67(1):4-11. PubMed ID: 22134373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities.
    Fredholm BB; Svenningsson P
    Neurology; 2003 Dec; 61(11 Suppl 6):S5-9. PubMed ID: 14663001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urate in Parkinson's disease: more than a biomarker?
    Chen X; Wu G; Schwarzschild MA
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):367-75. PubMed ID: 22580741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
    Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
    ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
    Jenner P
    Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can adenosine A
    Jenner P; Mori A; Kanda T
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S28-S36. PubMed ID: 33349577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.